ETS transcription factors ETV2, FLI1, and ERG1 specify pluripotent stem cells into induced vascular endothelial cells (iVECs). However, iVECs are unstable and drift toward nonvascular cells. We show that human midgestation c-Kit À lineage-committed amniotic cells (ACs) can be reprogrammed into vascular endothelial cells (rAC-VECs) without transitioning through a pluripotent state. Transient ETV2 expression in ACs generates immature rAC-VECs, whereas coexpression with FLI1/ERG1 endows rAC-VECs with a vascular repertoire and morphology matching mature endothelial cells (ECs). Brief TGFb-inhibition functionalizes VEGFR2 signaling, augmenting specification of ACs into rAC-VECs. Genome-wide transcriptional analyses showed that rAC-VECs are similar to adult ECs in which vascular-specific genes are expressed and nonvascular genes are silenced. Functionally, rAC-VECs form stable vasculature in Matrigel plugs and regenerating livers. Therefore, short-term ETV2 expression and TGFb inhibition with constitutive ERG1/FLI1 coexpression reprogram mature ACs into durable rAC-VECs with clinical-scale expansion potential. Banking of HLA-typed rAC-VECs establishes a vascular inventory for treatment of diverse disorders.
INTRODUCTION
The generation of human endothelial cells (ECs) from nonvascular cell sources has great therapeutic potential for treatment of injured organs. Furthermore, this approach would help to identify developmental pathways that modulate the hierarchical specification of organotypic adult ECs. However, the cultivation of stable ECs to clinical scale has not been achieved. Adultderived ECs have limited expansion potential. Likewise, differentiation of pluripotent stem cells, including induced pluripotent stem cells (iPSC) and human embryonic stem cells (hESCs), into induced vascular endothelial cells (iVECs) results in the generation of ECs that often proliferate poorly and drift into nonvascular lineages . Endothelial progenitor cells (EPCs) (Lyden et al., 2001; Rafii et al., 2002; Rafii and Lyden, 2003; Jin et al., 2006) and endothelial colony-forming cells (ECFCs) (Yoder et al., 2007) show significant expansion potential when grown in plasma (Reinisch et al., 2009 ). However, whether EPCs and ECFCs maintain their vascular identity after serial passaging is unknown. The shortcomings of existing strategies to generate mature and stable ECs are likely attributable to an insufficient appreciation of the transcription factors (TFs) and microenvironmental cues that establish durable tissue-specific vascular cells.
Members of the E-twenty six (ETS) family of TFs, including ETV2 (Lee et al., 2008) , FLI1 , and ERG (McLaughlin et al., 2001) , regulate vascular development and angiogenesis (De Val and Black, 2009) . These TFs drive the expression of genes associated with EC development and function. Adult ECs constitutively express several ETS factors, such as FLI1 and ERG (isoforms 1 and 2), whereas ETV2 is transiently expressed during embryonic development and is absent in adult ECs (Hollenhorst et al., 2007) . Although many of these TFs play key roles in vascular specification Pham et al., 2007) , it is not known whether they can switch on EC genes in nonvascular cells. Here, we show that differentiation of hESCs into iVECs (hESC/EC) is driven by the expression of ETV2, ERG1, and FLI1. However, iVECs generated by this approach are unstable and often lose their vascular identity.
In search of readily accessible and proliferative human cells for generation of authentic ECs, we identified human amniotic fluid-derived cells (ACs) as an ideal source of genetically diverse, nonvascular cells that are amenable to transcriptional reprogramming into vascular ECs (rAC-VECs). Freshly isolated ACs are obtained from individuals with broad genetic and ethnic backgrounds and are routinely cultured from the amniotic fluid of midgestation human fetuses for diagnostic purposes. They display high proliferative potential and can be HLA typed, cryopreserved, and stored for clinical use. Three subclasses of lineage-committed ACs have been identified: epithelioid (E type), amniotic fluid (AF type) and fibroblastic (F type) (Bossolasco et al., 2006) . E-type ACs presumably originate from fetal skin and mucosa, whereas F-type cells are derived from connective tissue. A rare subset of ACs is c-Kit + (CD117 + ) multipotent amniotic fluid stem cells (AFS) (De Coppi et al., 2007) . Incubation of naive ACs or preselected c-Kit + AFS in angiogenic culture conditions has led to the outgrowth of EC-like cells (Benavides et al., 2012; De Coppi et al., 2007; Kö nig et al., 2012; Zhang et al., 2009 . As such, we sought to identify TFs that are essential for vasculogenic specification of ECs and maintenance of iVECs. To this end, we used an established model of hESC differentiation into iVECs (Figure S1A available online). Using microarray profiling, we found that ETV2, FLI1, and ERG are key ETS family TFs that are expressed during iVEC generation ( Figure S1B ). Of note, ETV2 was expressed transiently, whereas FLI1 and ERG were constitutively expressed as hESCs transitioned to iVECs. Because, as compared to ERG2, ERG1 isoform was more abundant and functionally active in ECs (i.e., HUVECs and LSECs), we used ERG1 in protocols for the derivation of ECs from hESCs and ACs.
To determine whether enforced overexpression of ETV2, FLI1, and ERG1 (ETS-TFs) would augment the specification and stability of iVECs, hESCs were incubated with BMP2 and VEGF-A for 10 days to generate VEGFR2 + CD31 À VE-cadherin À cells, which are vascular precursors of iVECs. Subsequently, these cells were transduced with lentiviral vectors expressing cDNA for ETV2, FLI1, and ERG1 or control virus ( Figure S1A ). After culturing cells with VEGF-A, FGF-2, and TGFb inhibitor, we observed a modest increase in VEGFR2 + CD31 + VE-cadherin + iVECs (hESCs/ECs) among ETS-TF transduced cells compared to controls ( Figure S1C ). However, VEGFR2 + CD31 + VEcadherin + iVECs generated from both ETS-TF transduced and untransduced cells failed to proliferate beyond 3 weeks and often drifted into non-EC cell types. Therefore, despite enforced expression of ETS-TFs, hESC-derived iVECs are unable to sustain their proliferative potential and EC identity.
ETS-TFs Reprogram ACs into Proliferative and Stable rAC-VECs
We screened various adult and fetal nonvascular cells for their ability to be reprogrammed into ECs and found that EC-specific genes in adult fibroblasts and mesenchymal cells were only minimally induced by ETS-TFs (data not shown). However, midgestation mature lineage-committed ACs proved to be highly reprogrammable. Cultured ACs were transduced singularly and in combination with lentiviral ETS-TFs (ETV2, FLI1, and ERG1) ( Figure 1A ). As TGFb inhibition is essential in the derivation of iVECs from hESCs , ACs were also cultured in the presence of TGFb receptor inhibitor or neutralizing mAbs to TGFb ligands. Transduction of ACs with lentiviruses encoding ETV2, FLI1, or ERG1 led to adequate levels of corresponding mRNAs and protein for several months ( Figures S2A and S2B ). Whereas individual ETS-TFs turned on distinct EC genes (data not shown), ACs transduced with all three ETS-TFs displayed robust induction of multiple EC markers within 7 days, which lasted for 1 month and beyond ( Figure 1B ), suggesting that a combination of these factors was necessary to activate the full complement of genes associated with EC identity and maturity. by week 3 and increased to more than 6 billion cells by week 7 ( Figure 1D ). Following transduction with ETS-TFs and TGFb inhibition, rAC-VECs generated from ACs expanded to numbers nearly 30-fold higher than ETS-TF transduced or untransduced iVECs derived from hESCs (hESCs/ECs) ( Figure 1E ). Furthermore, a noticeable decrease in VE-cadherin + cells was seen over successive passages of ETS-TF transduced or untransduced hESC-derived iVECs compared to AC-derived rAC-VECs transduced with ETS-TFs ( Figure 1F ). This ''drift'' away from an EC phenotype within the hESC-derived iVEC population was verified by staining with smooth muscle a-actin (SMA) antibody (Figure 1G, boxes iii, iv, and vi) . ACs transduced with ETS factors were negative for this non-EC marker ( Figure 1g , box ii); rather, they exhibited the typical junctional VE-cadherin expression pattern found on other adult EC types, such as human umbilical vein ECs (HUVECs: Figure 1g , box v) and human adult liver sinusoidal ECs (LSECs; Figure S2C , box iii). Thus, ACs are more amenable to transcriptional reprogramming into stable ECs than are hESCs or adult fibroblasts.
ACs Are Devoid of EC Precursor Cells
Subsets of c-Kit + multipotent ACs, which compose % 1% of the AC population (De Coppi et al., 2007) , could potentially differentiate into ECs. Thus, to exclude the possibility that ECs are exclusively borne out from a multipotent or pluripotent subpopulation of ACs, we assessed the presence of pluripotency markers. The overwhelming majority of ACs was negative for OCT4 protein (Figure 2A ), confirming results from other groups (Jezierski et al., 2010) . Near undetectable mRNA expression levels for OCT4 ( Figure 2B , top), SOX2 ( Figure 2B , bottom), and NANOG (data not shown) further suggested that only a very small subset of ACs cells could be pluripotent or multipotent. Notwithstanding, to determine whether ECs could grow out from a pluripotent or pre-existing EC precursor cell, we cultured ACs without transduction of ETS-TFs in optimal EC growth media (EM) and TGFb inhibitor in normoxic conditions. We did not detect growth of any stable and fully committed ECs, verifying that cultured ACs are devoid of pre-existing vascular precursor cells that would generate authentic ECs (Figures S3A-S3B Figure 2D ). Immunostaining for EpCAM and VE-cadherin confirmed the transition from an epithelioid-type AC to a rAC-VEC ( Figure 2E ). Therefore, lineage-committed ACs are amenable to TF-mediated reprogramming into rAC-VECs.
ETS-TFs Induce Expression of a Vascular Signature in ACs
To assess the extent to which rAC-VECs acquire a vascular signature, we temporally measured VE-cadherin and VEGFR2 surface expression on emerging nascent rAC-VECs ( Figure 3A ). Four days after transducing TGF-b inhibited ACs with ETS-TFs, VE-cadherin + cells and, to a lesser extent, VEGFR2 + cells were generated ( Figure 3A , box ii). The percentage of cells expressing these markers increased significantly over several weeks (Figure 3A , boxes iv and vi) such that, after 4 weeks of reprogramming, the entire population ($99%) of transduced ACs was VE-cadherin + ( Figure 3B , box ii), of which nearly two-thirds also showed VEGFR2 expression. In addition, the size and shape of reprogrammed cells were similar to HUVECs ( Figure 3B , boxes iv-ix). We performed comparative genomic hybridization (CGH) analysis to assess the genomic integrity of day 28 rAC-VECs. This analysis revealed no genomic abnormalities, demonstrating that proliferating rAC-VECs are genetically stable ( Figure S4A ).
Optimal Stoichiometry of ETS-TF Expression Establishes Mature and Stable rAC-VECs
To create a homogenous population of mature rAC-VECs, we performed clonal analyses. rAC-VECs generated from ACs by transduction with ETS-TFs and TGFb inhibition were cultured for 21 days. We then isolated single cells expressing VE-cadherin, VEGFR2, and CD31 (VE-cad + VEGFR2 + CD31 + cells) and plated them at a density of one cell per well in 96-well plates for clonal expansion ( Figure 3C ). Within 21 days, $20% of single-cell clones showed expansion potential ( Figure 3D ), with individual clones yielding progeny with distinct phenotypes (Figure 3E, . Whereas cells from clones 1-3 were all VEcadherin + , CD31 expression varied greatly among these clones. Of note, nearly all clone 3 cells expressed CD31, whereas clone 1 yielded no CD31 + cells and clone 2 produced both CD31 + (18%) and CD31 À cells. Regardless of CD31 expression, all three clones expanded beyond 4 weeks ( Figure 3E , box v). These differences in EC marker induction could be due to differential levels of ETS-TF expression ( Figure 3E , boxes viviii). Both ERG1 and FLI1 were expressed in clone 3, suggesting that these factors turn on CD31 expression ( Figure 3E ). By contrast, ETV2 correlated negatively with CD31 expression. Thus, clone 3 had the appropriate combination of ETS-TF expression to induce VE-cadherin, VEGFR2, and CD31. Immunostaining of this clone confirmed the presence of VE-cadherin, CD31, ESAM, and JAM-A at cell junctions ( Figures 3F and S5A ). The disappearance of EpCAM in rAC-VECs ( Figure 3F ) indicates that the original nonvascular signature of these cells is being stripped away. Thus, expression of the proper stoichiometry of ETS-TFs is critical for generating rAC-VECs that are capable of achieving and maintaining optimal mature EC identity. 
Clonally Derived rAC-VECs Display a Transcriptome Profile that Is Similar to Mature ECs
Transcriptome sequencing (RNA-seq) was performed on rACVECs derived from ACs. These genome-wide analyses of rACVECs were then compared to the transcriptomes of HUVECs, LSECs, and non-EC types, including CD34 + hematopoietic cells (CD34   +   ) , bone marrow stromal cells (BMS), and naive control ACs (Amni ctrl). A significant number of vascular genes were upregulated in nonclonal (rAC-VEC) and clonal (rAC-VEC clone 3 and rAC-VEC clone 4) derived rAC-VECs compared to naive ACs ( Figure 4A) . Furthermore, the expression levels of these induced EC genes approached those seen in in-vitro-cultured HUVECs and LSECs, supporting the notion that rAC-VECs have attained a complete EC identity. Angiocrine factors that regulate EC-driven organ regeneration (Butler et al., 2010b; Ding et al., 2010 Ding et al., , 2011 Kobayashi et al., 2010 ) and tumor growth (Butler et al., 2010a) , including BMPs, Notch-ligands, IGFs, CSFs, Kit-ligand, and semaphorins, were all switched on in the rAC-VECs as well. Importantly, non-EC genes normally expressed in ACs, such as smooth muscle actin, musclin, and calponin-1, were silenced in rAC-VECs.
We then compared rAC-VEC and adult EC transcriptomes obtained from RNA-seq by performing three-dimensional multidimensional scaling (3D-MDS) ( Figure 4B and Movie S1) and hierarchical clustering analyses ( Figure 4C) . A tight association of clonal and nonclonal derived rAC-VECs was seen with HUVECs and LSECs, whereas BMS, lung-derived epithelial cells (Hackett et al., 2012) , and CD34 + hematopoietic cells showed no similarities to rAC-VECs. Of note, rAC-VECs did not express hematopoietic markers, ruling out the possibility that FLI1 and ERG1 induced hematopoietic identity. Therefore, genome-wide analyses demonstrate that enforced expression of ETV2, FLI1, and ERG1 with TGFb inhibition reprogram ACs into mature rAC-VECs (while silencing non-vascular genes) that resemble authentic mature ECs in global gene expression.
Short-Term TGFb Inhibition Permanently Functionalizes VEGFR2 Signaling in rAC-VECs ETS-TF-transduced ACs produced both TGFb and its receptors ( Figure 4A ), raising the possibility that an autocrine/juxtacrine loop might favor endothelial-mesenchymal transition (Endo-MT) and prevent rAC-VEC generation (Zeisberg et al., 2007) . Thus, ETS-TF-transduced ACs were cultured with and without neutralizing mAb to TGFb ligands or a TGFb inhibitor for 21 days. Even in the absence of exogenous TGFb ligand, basal levels of phosphorylated SMAD2 (P-SMAD2) were active in both control and ETS-TF-transduced ACs ( Figure 5A , lanes 1 and 2). This correlated with an absence of total and phosphorylated VEGFR2 protein in these TGFb-activated control and ETS-TF-transduced ACs ( Figure 5B , lanes 1-4). However, addition of mAb to TGFb ligands abrogated P-SMAD2 expression in rAC-VECs ( Figure 5A , lanes 7 and 8) upregulating VEGFR2 protein ( Figure 5B, lanes 11 and 12) . Importantly, rAC-VECs treated with mAb to TGFb ligands were responsive to VEGF-A stimulation, as shown by the phosphorylation of VEGFR2 (Figure 5B , lane 12). Despite supplementation with TGFb ligand ( Figure 5A , lanes 3-6) or pulsed with TGFb ligand stimulation ( Figure 5A , lanes 11-16), the presence of TGFb inhibitors prevented SMAD-2 phosphorylation, allowing for upregulation of VEGFR2 protein ( Figure 5B , lanes 7-10) and VEGF-A dependent phosphorylation ( Figure 5B , lanes 8 and 10). Of note, TGFb-activated rAC-VECs failed to attain EC morphology ( Figure 5C , box ii versus vi), whereas inhibition of TGFb signaling ( Figure 5C , boxes iii, iv, and v) endowed rAC-VECs with typical cobblestone morphology of EC monolayers ( Figure 5C , box vi). Thus, suppression of TGFb signaling functionalizes VEGFR2, preserving the vascular identity of rAC-VECs ( Figure 5D ). To determine whether continuous suppression of TGFb signaling was necessary to sustain rAC-VEC stability, we sequentially removed TGFb inhibition following ETS-TF transduction ( Figure 5E , left). Upon removal of TGFb inhibition at day 14 after transduction with ETS-TFs, we noticed a drop in VEGFR2 + cells during the ensuing 7 days of cell growth ( Figure 5E , left, white bar). However, when TGFb inhibition was removed at day 21 after transduction with ETS-TFs, the percentage of VEGFR2 + cells was retained ( Figure 5E , left, gray bar). Of note, manipulation of the TGFb pathway had no effect on VE-cadherin expression in rAC-VECs ( Figure 5E , right graph). Thus, abrogation of TGFb signaling for only 3 weeks is sufficient to permanently functionalize VEGFR2 signaling, maintaining long-term vascular identity and stability of rAC-VECs.
AC-Derived rAC-VECs Are Engraftable and Form Functional Perfused Vessels
We employed in vitro and in vivo models to assess whether rACVECs acquired full angiogenic potential. A tube formation assay using Matrigel as a substrate showed that day 21 rAC-VECs, but not naive ACs, were capable of forming tubes in vitro ( Figure 6A ). In addition, uptake of acetylated LDL (Ac-LDL) in rAC-VECs was similar to HUVECs ( Figure 6B ). We then tested for the ability of rAC-VECs to establish functional vasculature in two in vivo models. In one model, GFP-labeled day 42 rAC-VECs treated with either constant or short-term (21 days) TGFb inhibition in culture were loaded into (B) Three-dimensional MDS plots (3D MDS) were generated based on all pairwise distances between the global transcriptome-wide RNA-seq profiles of the samples shown here, including adult lung airway epithelial cells (Hackett et al., 2012) . This analysis shows a tight colocalization of clonal and nonclonal rAC-VECs with HUVECs and LSECs, thus indicating that their genome-wide expression profiles are highly similar. Conversely, nonvascular cell types, such as BMS, epithelial cells, and CD34 + hematopoietic cells, manifest no similarities to rAC-VECs. This analysis was not biased toward any gene set or processes: all > 30,000
RefSeq transcripts whose expression was quantified by RNA-seq were used to calculate distances between samples.
Matrigel plugs supplemented with VEGF-A and FGF-2 and were injected into immunocompromised NOD-SCID/IL2Rg À/À (NSG) mice ( Figure 6C ). Two weeks later, following intravital labeling of the vasculature by perfusion with Alexa568-Isolectin-B4 (10 min prior to sacrificing the mice) to identify patent vessels, Matrigel plugs were removed for analysis. Although naive ACs failed to form any capillaries ( Figure 6C , box ix), rAC-VECs treated with constant TGFb inhibition formed numerous functional vessels of varying caliber that anastomosed to the host vasculature. This was corroborated by colocalization of GFP signal with isolectin marker ( Figure 6C , box x). Similarly, rACVECs subjected to short-term TGFb inhibition showed an abundance of perfused vessels, underscoring their functionality in vivo ( Figure 6C , boxes xi and xii). Intrasplenic transplantation of ECs results in the engraftment of these cells into the liver sinusoidal vessels of mice that have undergone 70% partial hepatectomy . We used this in vivo model to interrogate the potential of rACVECs to incorporate long-term into the NSG mouse liver vasculature. Three months following intrasplenic transplantation of 5 3 10 5 GFP-labeled day 21 rAC-VECs, the mice were perfused with Alexa568-Isolectin-B4 to identify functional vessels. The number of perfused vessels engrafted with human GFP + rAC-VECs was determined by staining with mAbs specific to human CD31 (hCD31). Of note, we detected the presence of human GFP + Isolectin + hCD31 + rAC-VECs within 5%-10% of the regenerated liver sinusoidal vessels ( Figures 6D and 6E) . Thus, rAC-VECs can engraft and form durable patent vasculature in regenerating liver and establish functional perfused vessels in Matrigel plugs.
Function and Vascular Identity of rAC-VECs Is Preserved following Suppression of ETV2
ETV2 is transiently expressed during vascular development but is absent from mature fetal and adult ECs (Kataoka et al., 2011) . This is similar to our observation that rAC-VEC clones with low ETV2 levels and appropriate ERG1 and FLI1 levels represent populations of rAC-VECs that have achieved a mature vascular fate. Therefore, we examined whether short-term expression of ETV2, in conjunction with sustained expression of FLI1 and Erg1, might initiate reprogramming and then lock in permanent rAC-VEC identity. Using a doxycycline-dependent inducible (Tet-off) expression system to control ETV2 production (inducible ETV2: iETV2), iETV2/FLI1/ERG1 were transduced in ACs and cultured with TGFb inhibition for 14 days ( Figure 7A ). Next, cells were treated with doxycycline to suppress iETV2 expression without interfering with the expression of FLI1 and ERG1. ACs transduced with iETV2/FLI1/ERG1 expressed VEcadherin and CD31 in both dox-treated (iETV2-suppressed) and untreated cells beyond 4 weeks. Of note, 7 and 14 days after iETV2 was silenced, there was a higher percentage of VE-cadherin + CD31 + rAC-VECs compared to untreated rAC-VECs (Figure 7B) . Western blot analysis confirmed that ETV2 protein expression had indeed been silenced ( Figure 7C ) in dox-treated cells, indicating that ETV2 was no longer required for maintaining VE-cadherin expression in rAC-VECs. ERG1 synergizes with FLI1 to enhance and sustain CD31 expression in maturing rAC-VECs (Figures 3E and 7B) . Thus, its importance in reprogramming was assayed by transducing TGFb inhibited ACs with iETV2/FLI1 in the absence of ERG1 ( Figure S6A) . These cells were then split into two fractions at day 14, one of which was treated with doxycycline to suppress iETV2 expression without perturbing FLI1 expression. The emergence of VE-cadherin + CD31 + rAC-VECs generated from ACs transduced with iETV2/FLI1/ERG1 was accelerated compared to ACs lacking ERG1 transduction ( Figure 7B versus Figure S6B ). In day 28 iETV2/FLI1/ERG1 transduced ACs, in which iETV2 expression has been suppressed for 2 weeks, there was colocalization of VE-cadherin and CD31 ( Figure S6C ), as well as induction of numerous EC markers ( Figure S7A ). To assess the functionality of rAC-VECs generated via transient iETV2 expression in vivo, GFP-labeled iETV2/FLI1/ERG1 transduced ACs were cultured for 14 days, at which time iETV2 expression was suppressed. Subsequently, these cells were grown for another 28 days (d42 rAC-VECs), loaded into Matrigel plugs, and injected into NSG mice. Two weeks later, following intravital labeling of the vasculature by perfusion with Alexa568-Isolectin-B4, Matrigel plugs were removed for analysis ( Figures 7D and S7B ). There was colocalization of GFP, human CD31 (hCD31), and isolectin-marked cells, verifying that rACVECs no longer expressing iETV2 were still functional and capable of anastomosing to the host vasculature. Therefore, expression of ETV2 for only 2 weeks, along with constitutive coexpression of FLI1 and ERG1, confers rAC-VECs with permanent mature EC identity.
DISCUSSION ETS-TFs Reprogram ACs into Durable and Expandable
Mature rAC-VECs Derivation of abundant, engraftable human ECs could benefit patients with vascular disorders and uncover the identity of TFs and microenvironmental cues that drive organotypic EC specification. However, the purification and expansion of adult ECs is technically cumbersome. Current strategies to derive ECs from pluripotent stem cells even after transduction with ETS-TFs also generate unstable iVECs that have limited expansion potential (Figures 1E-1G) . Moreover, recent reports of directly reprogramming fibroblasts into EC-like cells (Margariti et al., 2012) still required the introduction of pluripotency factors. In the absence of these factors, fibroblasts failed to reprogram. Here, we have identified an alternative source of human lineage-committed ACs that can be reprogrammed into proliferative functional ECs without utilizing pluripotency factors, which we refer to as rAC-VECs. We show that enforced expression of FLI1/ERG1 with transient expression of ETV2 and TGFb inhibition reprograms ACs into rAC-VECs, which possess the (C) Hierarchical clustering of rAC-VEC and non-rAC-VEC samples. The same samples and pairwise distances between global transcriptome-wide RNA-seq profiles were used as those used for 3D-MDS by performing average linkage clustering. Like the 3D-MDS analysis, hierarchical clustering shows that clonal and nonclonal rAC-VECs, but not nonvascular cells cluster closely with HUVECs and LSECs. See also Movie S1. A) Western blot analysis of day 21 rAC-VECs that were treated ± TGFb ligand neutralizing mAB (TGFb ligand mAb, directed against b1, b2, and b3) or TGFb inhibition. This experiment was performed ± TGFb ligands (TGFb1 and TGFb3) to delineate the extent of TGFb receptor activity. ETS-TF-transduced ACs were incubated ± TGFb ligands (10 ng/ml) every 2 days (constant) with or without TGFb ligand mAb (10 mg/ml) or TGFb inhibitor. On day 21, ETS-TF-transduced ACs were serum starved for 4 hr and then treated ± one dose of TGFb ligands (10 ng/ml) for 45 min (pulse) ± TGFb ligand mAb or TGFb inhibitor. Following day 21 treatment, all cells were assayed for phosphorylated SMAD2 (P-SMAD2), total SMAD2, and GAPDH. (B) Western blot analysis of day 21 rAC-VECs that were treated ± constant TGFb ligands, with or without TGFb ligand mAb or TGFb inhibitor. On day 21, ETS-TFtransduced ACs were serum starved for 4 hr and then treated ± VEGF-A (50 ng/ml) for 5 min. Following day 21 treatment, cells were assayed for phosphorylated VEGFR2 (P-VEGFR2), total VEGFR2, and GAPDH. morphology and long-lasting angiogenic repertoire of generic and naive ECs ( Figure 7E) .
Transduction of ACs with ETS-TFs not only resulted in complete activation of a vascular signature, but also turned off nonvascular programs in ACs. rAC-VECs are highly proliferative and stable, capable of undergoing 6 3 10 4 -fold expansion in 50 days while maintaining expression of adhesion molecules, ECM proteins, and angiocrine factors, all of which establish their vascular function. With more amniocentesis being performed world-wide, we expect that genetically matched ACs will be available to generate sufficient numbers of durable and engraftable rAC-VECs for the treatment of vascular disorders and to orchestrate organ regeneration.
Lineage-Committed ACs Are Amenable to Reprogramming into rAC-VECs c-Kit + cells represent a rare AC subpopulation (%1%) that is multipotent (De Coppi et al., 2007 (De Val et al., 2008) . It is also plausible that midgestation ACs possess a uniquely plastic chromatin state, rendering them permissive to transcriptional reprogramming. Therefore, ACs provide for a universally reprogrammable and safe source of primary cells for the generation of tissue-specific lineages and help identify unrecognized chromatin states that are accessible to clusters of organotypic TFs.
ETS-TFs Switch on Vascular-Specific Genes and Silence the Expression of Nonvascular Genes in ACs
Hierarchical clustering and 3D-MDS analyses demonstrate that the transcriptome of rAC-VECs is highly similar to prototypical fetal (HUVEC) and adult (LSEC) mature ECs and differs drastically from nonvascular cells. Thus, rAC-VECs exclusively acquire the global transcriptome of a generic vascular cell type while simultaneously silencing their original nonvascular transcriptional signature.
ETS-TF-mediated suppression of nonvascular transcription programs in rAC-VECs is clinically relevant, as persistent expression of nonvascular genes may result in malfunction of in-vivoengrafted rAC-VECs predisposing to vascular deformity and thrombus formation. Indeed, engraftment of rAC-VECs into Matrigel plugs or regenerating mouse liver led to the generation of patent sinusoidal-like capillaries that manifested no evidence of thrombosis for a duration of 3 months. Thus, rAC-VECs have the capacity to adapt to the microenvironment within the liver sinusoids establishing durable perfused vessels.
ETS-TF-Mediated Generation of Functional rAC-VECs Requires Short-Term TGFb Inhibition for 3 Weeks
Transduction of ETS-TF into ACs without TGFb inhibition failed to generate functional proliferative rAC-VECs. Of note, rACVECs not only express TGFb1, -b2, -b3, and LTBPs, but also TGFbRII and TGFbRI, resulting in constitutive SMAD2 phosphorylation. Active TGFb signaling favors Endo-MT, hindering the formation of rAC-VECs. TGFb also modulates stability of FLI1 protein and its capacity to bind DNA (Asano and Trojanowska, 2009) . TGFb signaling abrogates VEGFR2 expression in ECs, impairing proliferative and vasculogenic functions. Remarkably, short-term inhibition of TGFb signaling for 3 weeks was sufficient to permanently functionalize VEGFR2 and possibly other unknown EC-specific signaling and transcriptional pathways. Thus, reprogramming of ACs not only requires enforced expression of TFs, but also modulation of signaling pathways to establish stable rAC-VECs.
Transient ETV2 Expression with Sustained FLI1 and ERG1 Maintains Vascular Maturity and Stability of rAC-VECs Adult ECs do not express ETV2 but do constitutively express FLI1 and ERG1 (De Val and Black, 2009) , suggesting that transient expression of ETV2 is sufficient to specify and lock in the vascular fate. Similarly, ETV2 expression in ACs for 2 weeks was sufficient to switch on multiple downstream EC-specific ETS family TFs. The genes turned on by ETV2 were factors that are essential for specification of ACs into functional ECs, including VEGFR2, VE-cadherin, TIE1, TIE2, EDG-1, VEGFR1, and Notch-signaling pathway genes.
Of note, ETV2 alone was insufficient to switch on all EC genes. FLI1 and ERG1, meanwhile, turned on EC genes associated with maturity, such as CD31, ECMs, and angiocrine factors. Hence, ETV2 specifies ACs into immature endothelium, whereas FLI1 and ERG1 induce genes that render these progenitors into mature functional ECs ( Figure 7E ).
It is unknown how genes targeted by ETV2 are sustained after ETV2 expression is extinguished. One intriguing possibility is that genes bound by ETV2 are epigenetically marked for sustained activation. Alternatively, upon silencing of ETV2 expression, FLI1, ERG1, and/or other unrecognized TFs arrive at formerly ETV2-bound genomic targets to maintain long-term expression. Indeed, deletion of FLI1 gene in adult ECs results in downregulation of certain vascular-specific genes that modulate EC identity (Asano et al., 2010) . Thus, as we demonstrate here, constitutive expression of FLI1 plays a seminal role in stabilizing rAC-VECs.
Similarly, ERG may also maintain the quiescence of ECs by repressing the activity of NF-kB (Dryden et al., 2012; Yuan et al., 2009 ) and safeguarding vascular permeability by enforcing expression of Claudin-5 (Yuan et al., 2012) and VE-cadherin (Birdsey et al., 2008) . ERG is expressed in at least two isoforms (ERG1 and ERG2). Because as compared to ERG2, the expression ERG1 is 5-fold higher in ECs and accelerates the expression of mature genes, such as CD31, we focused on ERG1 to drive ACs into mature rAC-VECs. Whether coexpression of ERG2 in addition to ERG1 plays a physiological role in enhancing acquisition of mature vascular identity is unknown.
FLI1 and ERG have been implicated in the specification of hematopoietic cells (De Val and Black, 2009; Lee et al., 2008) . Of note, SCL/TAL1, VAV3, and LMO2 genes that are coexpressed in both ECs and hematopoietic cells were also induced in rAC-VECs. However, combinatorial transduction of ETV2 concomitant with FLI1/ERG1 (along with TGFb inhibition) did not induce hematopoietic-specific genes (i.e., CD45, Thrombopoietin receptor) in rAC-VECs. Thus, transient expression of ETV2 may alter FLI1/ERG1 predilection for hematopoietic specification, directing nascent rAC-VEC transition toward a vascular fate.
Optimal Ratios of ETS-TFs Augment Production of Mature rAC-VECs
Transduction of ACs with ETV2 in the absence of ERG1 and FLI1 is sufficient to initiate transcription of EC-specific genes as well as stimulate the proliferation of ACs, thereby augmenting their transition into rAC-VECs. However, ETV2 alone fails to turn on genes that confer rAC-VECs' vascular maturity. On the other hand, whereas singular transduction with either FLI1 or ERG1 failed to confer EC identity upon ACs and induce cellular expansion, cotransduction of ERG1/Fli1 with transient ETV2 was effective in generating mature and proliferative rAC-VECs. Indeed, based on the clonal analyses ( Figures 3C-3E ), we found that proper stoichiometric ratios of ETV2 relative to FLI1 and ERG1 were key to the generation of proliferative as well as mature rAC-VECs.
By day 21, a time point in which rAC-VECs have achieved their maximal maturity, the clonal efficiency of mature rAC-VECs, such as clone 3, is $20%. Genome-wide 3D-MDS analyses demonstrated that the transcriptomes of clone 3 and other similar clones match those of HUVECs and LSECs. Although the majority of genes expressed in vascular cells were induced in these clones, certain genes such as eNOS and GATA3 were not completely induced. Tissue-specific microenvironmental cues may be necessary to induce expression of these genes. Nonetheless, the remarkable proliferative capacity (ETV2 dependent) and vascular maturity (ERG1/FLI1 dependent) of specific rAC-VEC clones suggest that the optimal combinatorial ratios of these ETS-TFs within ACs is the major determinant of generating plentiful stable rAC-VECs.
Expression of FLI1 and ERG1 Is Not Associated with Malignant Transformation Aberrant expression of FLI1 can induce leukemia (Cui et al., 2009) and Ewing Sarcoma (Zhang et al., 1993) . ERG overexpression has also been associated with leukemias (Martens, 2011) . However, in vivo transplantation of rAC-VECs expressing FLI1 and ERG1 in Matrigel plugs for 14 days or in regenerating liver for 3 months did not lead to emergence of angiomas or angiosarcomas. Long-term expansion of rAC-VECs beyond 80 days revealed no evidence of malignant transformation. Employing CGH, we also showed that expansion of rAC-VECs beyond 28 days did not lead to any chromosomal abnormalities. Furthermore, as rAC-VEC phenotype is retained even after removal of ETV2 expression and TGFb-inhibition, this indicates that rACVECs represent a durable and expandable cell population that provides for a safe source of vascular cells.
Potential Use of rAC-VECs for Therapeutic Vascularization and Organ Regeneration
The vascular repertoire of rAC-VECs approximates that of generic naive ECs. As such, rAC-VECs may have the vascular plasticity to undergo further tissue-specific specialization once reintroduced into the microenvironment of a given organ. In support of this premise, we showed that rAC-VECs acquired the morphology of sinusoidal ECs upon transplantation into regenerating liver. Ultimately, identification of the TFs that endow ECs with a tissue-specific signature will enable generation of rAC-VECs that will adapt to the physiological and metabolic needs of a particular organ. In this regard, we have identified a readily available source of human lineage-committed proliferative cells with allogeneic compatibility that are amenable to reprogramming into abundant functional rAC-VECs. (C) In vivo tube formation assay of GFP-labeled control ACs (i, v, and ix), GFP-labeled day 42 rAC-VECs (ii, vi, and x), and GFP-labeled day 42 rAC-VECs in which TGFb inhibition was removed at day 21 (sample A: iii, vii, and xi; sample B: iv, viii, and xii). Cells were loaded separately into Matrigel plugs and implanted subcutaneously into NSG mice. Two weeks after implantation, mice were intravenously perfused with Alexa568-Isolectin-B4. After 10 min, plugs were removed and sectioned. Immunofluorescence shows control ACs and rAC-VECs in green (GFP), intravital labeling of perfused vasculature in red (Isolectin), and nuclear counterstain (DAPI) in blue. Scale bar, 50 mm. White arrows indicate the colocalization of GFP-and isolectin-marked (anastomosed) vessels. Orange arrows indicate only isolectin-marked host mouse vessels. (D and E) In vivo engraftment of day 21 rAC-VECs (GFP labeled) into liver sinusoidal vessels of two mice. After performing 70% partial hepatectomy on NSG mice, 5 3 10 5 GFP-labeled day 21 rAC-VECs were transplanted via intrasplenic route, which will drain into portal circulation and incorporate into liver vasculature. Thirty minutes later, the spleen was removed to prevent migration back to spleen. Three months following transplantation, the mice were perfused with Alexa568-Isolectin-B4 and the liver was removed. Immunofluorescence shows control rAC-VECs in green (GFP), intravital labeling of perfused vasculature in red (Isolectin), human CD31 staining in cyan, and nuclear counterstain (DAPI) in blue. Liver sample 1 (D) was imaged at low magnification (i-iv: scale bar, 50 mm). Liver sample 2 (E) was imaged at low (i-iv: scale bar, 50 mm) and high magnification (v-viii: scale bar, 25 mm). White arrows indicate the colocalization of GFP-, CD31-, and isolectin-marked (anastomosed) vessels. Orange arrows indicate only isolectin-marked host mouse vessels. The generation of rAC-VECs will not only increase our understanding of the hierarchy of transcriptional pathways involved in the induction and maintenance of organ-specific ECs, but also open the door for vascularization of ischemic tissues. With thousands of amniocenteses being performed worldwide each year, this ensures that sufficient genetically matched ACs will be available for reprogramming into rAC-VECs that may benefit a broad cross-section of the ethnically diverse population. Given that ACs and rAC-VECs could be HLA typed, cryopreserved, and publicly banked, these cells could establish an inventory for generating abundant vascular cells for promoting angiocrinedependent organ regeneration as well as lay the foundation for treating genetically diverse populations of patients with vascular disorders.
EXPERIMENTAL PROCEDURES

Reprogramming Protocol
Cell Culture Human embryonic stem cells (hESCs) were maintained on Matrigel using hESC medium (KOSR) conditioned by mouse embryonic fibroblasts (MEF, Chemicon) and were grown at 37 at 5% CO 2 . Amniotic cells (ACs) were cultured in amniotic media (AM) and grown at 37 at 5% CO 2 .
In reprogramming assays, ACs were cultured in endothelial growth media (EM: medium 199, 15% FBS, 20 mg/ml endothelial cell supplement, 13 Pen/ Strep, and 20 units/ml Heparin) and, where indicated, supplemented with 5 mM TGFb inhibitor or 10 mg/ml TGFb ligand-neutralizing mAB (R&D) to inhibit TGFb signaling. Human liver sinusoidal ECs (LSECs, ScienCell) were cultured in EM with 20% FBS. Human umbilical vein ECs (HUVECs) were obtained as previously described (Rafii et al., 1994 (Rafii et al., , 1995 and cultured in EM with 20% FBS. Culture plates were coated with 1 mg/ml Fibronectin (Sigma), and cells were grown at 37 and at 5% CO 2 and 5% O 2 . See Extended Experimental
Procedures for details of strains and media.
Cytokine Treatments
For TGFb experiments, 10 ng/ml TGFb ligands b1 and b3 (R&D) were added for indicated times. For VEGFR2 phosphorylation experiments, 50 ng/ml VEGF-A was added for 5 min. For acetylated-LDL uptake assays, cells were treated with 10 mg/ml DiI-labeled Ac-LDL (Biomedical Technical Inc).
Lentiviral Vectors and Transduction Strategy
ETV2, ERG1, and FLI1 cDNAs were cloned into the pCCL-PGK lentivirus vector. A triple Flag-tag was subcloned into the ETV2 construct at the amino terminus. For conditional expression/suppression experiments, Flagtag ETV2 was resubcloned into an inducible pTA-dependent construct, in which suppression of Flag-tag ETV2 was achieved via treatment with 2 mg/ml doxycycline (Clonetech). A scrambled shRNA construct was cloned into the pLKO vector for use as a control. See Extended Experimental Procedures for details of construct strategy and lentiviral production.
In Vitro Matrigel Tubulogenesis and In Vivo Angiogenesis Assays
To test the capacity of rAC-VECs to undergo tubulogenesis in vivo, ACs infected with ETS-TFs were transduced with GFP-lentivirus and were mixed with Matrigel (BD), 100 ng/ml of VEGF-A, and 50 ng/ml of FGF-2 and were subcutaneously implanted at the flanks of NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ (NOD-SCID/IL2Rg À/À , NSG) mice (Jackson Laboratories). To test the capacity of rAC-VECs to functionally incorporate into regenerating liver sinusoidal vasculature, GFP-labeled rAC-VECs were intrasplenically injected into NSG mice 2 days after they were subjected to 70% partial hepatectomy, as previously described . At 30 min after intrasplenic injection, the spleen was removed. Two weeks (Matrigel plugs) or three months (intrasplenic) after injection of GFP-labeled rAC-VECs, the mice were injected intravenously with Isolectin-B4 conjugated with Alexa568 (Invitrogen) (2 mg/kg) and were sacrificed 10 min later. The Matrigel plug or liver was then fixed in 4% paraformaldehyde, followed by 48 hr saturation in 30% sucrose. 20 mm cryosections were made and counterstained with Hoechst 33342. Incorporation of GFPlabeled rAC-VECs was identified, and functional engraftment into host vasculature was revealed by costaining with Isolectin-B4 fluorescence. Antihuman CD31 (BD) staining was performed to distinguish rAC-VECs from host mouse ECs. Fluorescent signal was analyzed by confocal microscopy (710 META Zeiss). The area of GFP-positive field was quantified by ImageJ, and the number of isolectin-positive functional vessels was determined by counting cells present in three fields of view taken at random. For in vitro assays, 200,000 rAC-VECs were seeded on Matrigel-coated plates (200 ml), and tubulogenesis was determined as previously described .
Immunofluorescence/Western Blot Analysis Samples were stained as previously described . In brief, samples were permeabilized in PBS-Tween and blocked in 5% donkey serum. Samples were incubated for 1 hr with conjugated antibodies in blocking solution, washed, and counterstained for nucleic acids by DAPI or ToPro3 (Invitrogen) for imaging. Western blot analysis was performed as previously described . See Extended Experimental Procedures for details of antibodies used in these assays. (C) iETV2 suppression by Dox was confirmed by western blot analysis. (D) In vivo tube formation assay of GFP-labeled day 42 rAC-VECs in which iETV2 expression was suppressed at day 14. rAC-VECs were subjected to Matrigel plug analysis in NSG mice as previously described in Figure 6C . Immunofluorescence micrographs show rAC-VECs in green (GFP), intravital labeling of perfused vasculature in red (Isolectin), human CD31 staining in cyan, and nuclear counterstain (DAPI) in blue. Sample A was imaged at low magnification (i-iv: scale bar, 100 mm). Sample B was imaged at high magnification (v-viii: scale bar, 50 mm). White arrows indicate the colocalization of GFP-, CD31-and isolectin-marked (anastomosed) vessels. Orange arrows indicate only isolectin-marked host mouse vessels.
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(E) Modular ETS-TF-mediated reprogramming of ACs into abundant mature rAC-VECs. When cultured in optimal EC conditions, naive ACs do not reprogram into ECs, nor do they proliferate (bottom). In the absence of TGFb inhibition, ETS-TF-transduced ACs are VE-cad + but fail to express other essential EC-markers, including functional VEGFR2, resulting in the generation of VEGF-A-unresponsive EC-like precursors (shaded panel). Transient inhibition of TGFb signaling for $3 weeks upregulates and functionalizes VEGFR2, allowing for VEGF-A-dependent signaling events to proceed (top). Coexpression of FLI1/ERG1 with ETV2 along with TGFb inhibition maintains VE-cadherin and VEGFR2 expression; however, constitutive ETV2 inhibits CD31 expression, resulting in the production of immature EC progenitors (top, low). Upon suppression of ETV2 at day 14, CD31 is upregulated, facilitating the generation of mature rAC-VECs (top, high). Error bars represent standard error of triplicate samples. See also Figures S6 and S7 .
